Pharma major Dr Reddy’s Laboratories (DRL) today said it has expanded its manufacturing operations in the United Kingdom.
The Custom Pharmaceutical Services (CPS) business has been expanded in the areas of development and manufacture of NCE (New Chemical Entities) APIs for use in pre-clinical through to commercial development at its facility in Mirfield, UK, a company statement said.
Reuters
Equipped with state-of-the-art systems, the UK plant operates with a very high level of control and has been designed with the latest manufacturing compliance standards in mind, it said.
Commenting on the development, R Ananthanarayanan, President Pharmaceutical Services and Active Ingredients business, Dr Reddy’s, said, “This expansion builds on our commitment to expand operations in UK and provide a superior network of manufacturing to support our global customer base.
“We have invested in multiple technology areas and the expansion will add significant value in the area API manufacturing.” The Hyderabad-based drugmaker has eight API manufacturing facilities, all approved by health regulator FDA. Of these, six plants are in India and one each in Mexico and UK, the release added.
PTI
